Intragastric Balloon-Induced Satiety is Not Mediated by Modification in Fasting or Postprandial Plasma Ghrelin Levels in Morbid Obesity
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The BioEnterics Intragastric Balloon (BIB) has been proposed as an adjuvant therapy for the short-term treatment of obesity. The temporal pattern of BIB-induced satiety and whether this effect is mediated by modification of ghrelin levels is unknown.
Patients with treatment-resistant morbid obesity were invited to participate in a randomized, double-blind, sham-controlled trial of 4-month duration. Anthropometric and biochemical parameters, estimation of energy intake, and pre- and postprandial evaluation of satiety were required monthly. Ghrelin response after a standard mixed meal was scheduled prior to and 4 weeks after the endoscopic procedure.
21 out of 22 enrolled patients completed the study (17 women, 5 men; 35.9 ±–.9 years; BMI 50.4 ±–.8 kg/m2). Pre-intervention weight decreased from 143.8 ±–1.2 kg to 131.1 ±–2.6 kg in Group Balloon (P–lt;–.001) and from 138.8 ±–4.5 kg to 129.9 ±–5.6 kg in Group Sham (P–lt;–.01) at the end of the study. Weight loss was not significantly different in Group Balloon and Group Sham at any time-point of the follow-up. Only patients from Group Balloon showed a temporary increased pre- and postprandial satiety, which was maximal at 4 weeks after the intervention. Total area under the curve, fasting and postprandial plasma ghrelin were not significantly different between groups at inclusion or 4 weeks after follow-up. No correlation was found between any of the satiety scores at any time-point with their comparable ghrelin levels.
BIB induces a temporary sense of satiety in morbidly obese patients which is not mediated by modification of fasting or postprandial levels of plasma ghrelin.
- Bray GA, Tartaglia LA. Medicinal strategies in the treatment of obesity. Nature 2000; 404: 672–.
- Pereira Cunill JL, Garcia-Luna PP, Astorga Jimenez R. Pros and cons of surgery in obesity. Rev Clin Esp 2003; 203: 567–. CrossRef
- Totte E, Hendrickx L, Pauwels M et al. Weight reduction by means of intragastric device: experience with the bioenterics intragastric balloon. Obes Surg 2001; 11: 519–3. CrossRef
- Doldi SB, Micheletto G, Perrini MN et al. Treatment of morbid obesity with intragastric balloon in association with diet. Obes Surg 2002; 12: 583–. CrossRef
- Loffredo A, Cappuccio M, De Luca M et al. Three years experience with the new intragastric balloon, and a preoperative test for success with restrictive surgery. Obes Surg 2001; 11: 330–. CrossRef
- Sallet JA, Marchesini JB, Paiva DS et al. Brazilian multicenter study of the intragastric balloon. Obes Surg 2004; 14: 991–. CrossRef
- Genco A, Bruni T, Doldi SB et al. BioEnterics Intragastric Balloon: The Italian experience with 2,515 patients. Obes Surg 2005; 15: 1161–. CrossRef
- Weiner R, Gutberlet H, Bockhorn H. Preparation of extremely obese patients for laparoscopic gastric banding by gastric-balloon therapy. Obes Surg 1999; 9: 261–. CrossRef
- Busetto L, Segato G, De Luca M et al. Preoperative weight loss by intragastric balloon in super-obese patients treated with laparoscopic gastric banding: a case-control study. Obes Surg 2004; 14: 671–. CrossRef
- Alfalah H, Philippe B, Ghazal F et al. Intragastric balloon for preoperative weight reduction in candidates for laparoscopic gastric bypass with massive obesity. Obes Surg 2006; 16: 147–0. CrossRef
- Kojima M, Hosoda H, Date Y et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656–0. CrossRef
- Nakazato M, Murakami N, Date Y et al. A role for ghrelin in the central regulation of feeding. Nature 2001;409:194–. CrossRef
- Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000; 407: 908–3. CrossRef
- Cummings DE, Purnell JQ, Frayo RS et al. A preprandial rise in plasma ghrelin levels suggests a role in initiation in humans. Diabetes 2001; 50: 1714–. CrossRef
- Tschop M, Weyer C, Tataranni PA et al. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001; 50: 707–. CrossRef
- Cummings D, Weigle D, Frayo S et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002; 346: 1623–2. CrossRef
- Le Roux CW, Patterson M, Vincent RP et al. Postprandial plasma ghrelin is suppressed proportional to meal calorie content in normal-weight but not obese subjects. J Clin Endocrinol Metab 2005; 90: 1068–1. CrossRef
- Gastrointestinal surgery for severe obesity. National Institutes of Health Consensus Development Conference Draft Statement. Obes Surg 1991; 1: 257–5.
- SEEDO–000 consensus for the evaluation of overweight and obesity and the establishment of criteria for therapeutic intervention. Sociedad Espanola para el Estudio de la Obesidad. Med Clin (Barc) 2000; 115: 587–7.
- Romero H, Martinez-Brocca MA, Pereira JL, Garcia-Luna PP. Pharmacological treatment of obesity. Rev Esp Obes 2005; 3: 13–5.
- Suerbaum S, Michetti P. Medical progress: Helicobacter pylori infection. N Engl J Med 2002; 347: 1175–6. CrossRef
- Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–7.
- Benjamin SB, Maher KA, Cattau EL et al. A doubleblind controlled trial of the Garren-Edwards gastric bubble: an adjunctive treatment for exogenous obesity. Gastroenterol 1988; 95: 581–.
- Meshkinpour H, Hsu D, Farivar S. Effect of gastric bubble as a weight reduction device: a controlled crossover study. Gastroenterol 1988; 95: 589–2.
- Mathus-Vliegen EMH, Tytgat GNJ. Intragastric balloons for morbid obesity: results, patient tolerance and balloon life span. Br J Surg 1990; 77: 76–. CrossRef
- Geliebter A, Melton PM, McCray RS et al. Clinical trial of silicone-rubber gastric balloon to treat obesity. Int J Obes 1991; 15: 259–6.
- Hodson RM, Zacharoulis D, Goutzamani E et al. Managment of obesity with the new intragastric balloon. Obes Surg 2001; 11: 327–. CrossRef
- Erdman J, Lippl F, Schusdziarra V. Differential effect of protein and fat on plasma ghrelin levels in man. Regul Pept 2003; 116: 101–. CrossRef
- Mion F, Napoleon B, Roman S et al. Effects of intragastric balloon on gastric emptying and plasma ghrelin levels in non-morbid obese patients. Obes Surg 2005; 15: 510–. CrossRef
- Herve J, Wahlen CH, Schaeken A et al. What becomes of patients one year after the intragastric balloon has been removed? Obes Surg 2005; 15: 864–0. CrossRef
- Doldi SB, Micheletto G, Perrini MN et al. Intragastric balloon: another option for treatment of obesity and morbid obesity. Hepatogastroenterology 2004; 51: 294–.
- Mathus-Vliegen EMH, Tytgat GNJ. Intragastric balloon for treatment-resistant obesity: safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon-free follow up. Gastrointest Endosc 2005;61:19–7. CrossRef
- Genco A, Cipriano M, Bacci V et al. BioEnterics® Intragastric Balloon: a short-term, double-blind, randomised, controlled, crossover study on weight reduction in morbidly obese patients. Int J Obes 2006; 30: 129–3. CrossRef
- Intragastric Balloon-Induced Satiety is Not Mediated by Modification in Fasting or Postprandial Plasma Ghrelin Levels in Morbid Obesity
Volume 17, Issue 5 , pp 649-657
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Morbid obesity
- intragastric balloon
- bariatric surgery
- Industry Sectors
- Author Affiliations
- 1. Department of Endocrinology and Nutrition, University Hospital Virgen del Rocio, Seville, Spain
- 2. Department of Gastroenterology, University Hospital Virgen del Rocio, Seville, Spain
- 3. Department of Clinical Biochemistry, University Hospital Virgen del Rocio, Seville, Spain
- 4. Section of Endocrine Surgery, Department of Surgery, University Hospital Virgen del Rocio, Seville, Spain
- 5. Department of Nuclear Medicine, University Hospital Virgen del Rocio, Seville, Spain
- 6. Section of Clinical Nutrition. Department of Endocrinology and Nutrition, Hospital Universitario Virgen del Rocio, Avenida Manuel Siurot, s/n. 41013, Seville, Spain